The quality of life and cost-effectiveness of treatment after a serious neurosurgical illness by Malmivaara, Kirsi
  
The quality of life and cost-effectiveness of treatment after a 
serious neurosurgical illness 
 
 
Kirsi Malmivaara 
 
Department of Neurosurgery, Helsinki University Central Hospital 
Faculty of Medicine 
University of Helsinki 
Helsinki, Finland 
 
The National Graduate School of Clinical Investigation 
 
 
 
 
 
 
ACADEMIC DISSERTATION 
 
To be presented,  
with permission of the Faculty of Medicine of the University of Helsinki 
 for public examination  
in the Töölö Hospital  
on January 31th 2014, at 12 noon. 
 
 
 
1 
 
Helsinki 2014 
Supervised by Docent Jari Siironen  
  Department of Neurosurgery of  
Helsinki University Central Hospital  
Helsinki, Finland 
 
and 
 
Professor Juha Hernesniemi 
Department of Neurosurgery of  
Helsinki University Central Hospital  
Helsinki, Finland 
 
 
 
Reviewed by Docent Esa Heikkinen 
  Department of Neurosurgery 
Oulu University Central Hospital 
Oulu, Finland 
 
  and 
 
  Docent Antti Malmivaara 
National Institute for Health and Welfare 
  University of Oulu 
  Oulu, Finland 
 
 
 
Official opponent Professor (emer.) Martti Kekomäki 
Helsinki University Central Hospital  
University of Helsinki  
Helsinki, Finland 
 
 
 
 
 
 
 
ISBN 978-952-10-9688-4 (paperback)  
ISBN 978-952-10-9689-1 (PDF) 
http://ethesis.helsinki.fi 
Unigrafia Oy 
Helsinki 2014 
2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 
 
CONTENTS 
ORIGINAL ARTICLES ....................................................................................................5 
ABBREVIATIONS AND DEFINITIONS ........................................................................6 
ABSTRACT .......................................................................................................................8 
TIIVISTELMÄ................................................................................................................. 10 
INTRODUCTION ........................................................................................................... 12 
REVIEW OF THE LITERATURE .................................................................................. 14 
Economic evaluation .................................................................................................... 14 
Cost-minimization analysis ....................................................................................... 16 
Cost-effectiveness analysis ......................................................................................... 16 
Cost-utility analysis ................................................................................................... 16 
Cost-benefit analysis .................................................................................................. 17 
Quality-adjusted life year .............................................................................................. 17 
Evaluating health-related quality of life ..................................................................... 18 
Health utility instruments .......................................................................................... 18 
EQ-5D ....................................................................................................................... 20 
Costs analysis ................................................................................................................ 22 
Diagnosis-related groups ........................................................................................... 23 
Evaluation of the effectiveness of an intervention .......................................................... 23 
Cost-effectiveness threshold .......................................................................................... 25 
Comparative effectiveness research ............................................................................... 26 
Evaluation of neurosurgical treatments ......................................................................... 27 
Cost-effectiveness studies of acute neurosurgical illnesses .............................................. 27 
Neurosurgical intensive care unit ............................................................................... 27 
Traumatic brain injury ............................................................................................... 28 
Decompressive craniectomy ...................................................................................... 30 
Aneurysmal subarachnoid haemorrhage .................................................................... 32 
Other acute illnesses and cost-effectiveness ................................................................ 34 
AIMS OF THE PRESENT STUDY ................................................................................ 35 
MATERIALS AND METHODS ..................................................................................... 37 
Patient selection for the Step-down unit study ............................................................... 37 
Patient selection for the DC studies ............................................................................... 38 
Patient selection for the SAH study ............................................................................... 39 
Data collection and follow-up methods ......................................................................... 39 
Costs ............................................................................................................................. 40 
Calculation of QALYs and costs ................................................................................... 41 
4 
 
Statistical analysis ......................................................................................................... 43 
RESULTS ........................................................................................................................ 44 
Mortality and outcome .................................................................................................. 45 
Health-related quality of life, QALYs and costs ............................................................ 47 
Additional findings ....................................................................................................... 50 
DISCUSSION .................................................................................................................. 51 
Economic evaluation .................................................................................................... 51 
Evaluating health-related quality of life ......................................................................... 51 
Quality-adjusted life year .............................................................................................. 52 
EQ-5D .......................................................................................................................... 52 
Costs analysis ................................................................................................................ 53 
effectiveness of an intervention ...................................................................................... 54 
Cost-effectiveness threshold .......................................................................................... 54 
Consolidated reporting standards .................................................................................. 55 
Step-down unit study .................................................................................................... 56 
DC after SAH study ...................................................................................................... 57 
DC after TBI study ........................................................................................................ 58 
SAH study .................................................................................................................... 59 
CONCLUSIONS ............................................................................................................. 60 
ACKNOWLEDGEMENTS ............................................................................................ 61 
REFERENCES ................................................................................................................ 62 
 
 
 
 
 
 
 
 
 
 
 
 
5 
 
ORIGINAL ARTICLES 
 
I 
Malmivaara K, Hernesniemi J, Salmenperä R, Öhman J, Roine RP, Siironen J. 
Survival and outcome of neurosurgical patients requiring ventilatory support after 
intensive care unit stay. Neurosurgery 2009; 65: 530-537. 
II 
Malmivaara K, Öhman J, Kivisaari R, Hernesniemi J, Siironen J. Cost-
effectiveness of decompressive craniectomy in non-traumatic neurological 
emergencies. European Journal of Neurology 2011; 18: 402-409.  
III 
Malmivaara K, Kivisaari R, Hernesniemi J, Siironen J. Cost-effectiveness of 
decompressive craniectomy in traumatic brain injuries. European Journal of Neurology 
2011; 18: 656-662.  
IV 
Malmivaara K, Juvela S, Hernesniemi J, Siironen J. Health-related quality of life 
and cost-effectiveness of treatment in subarachnoid haemorrhage. European Journal 
of Neurology 2012; 19:1455-61. 
  
 
 
 
 
 
 
 
 
 
 
6 
 
ABBREVIATIONS AND DEFINITIONS 
 
 
€ Euro 
15D 15D HRQoL instrument 
ACA Anterior cerebral artery 
ACoA Anterior communicating artery 
AVM 
CBA 
CE 
CEA 
CER 
CMA 
CUA 
Arteriovenous malformation 
Cost-benefit analysis 
Cost-effectiveness 
Cost-effectiveness analysis 
Comparative effectiveness research 
Cost-minimization analysis 
Cost-utility analysis 
CT 
DALY 
Computed tomography 
Disability adjusted life year 
DC 
DRG 
EBM 
Decompressive craniectomy 
Diagnosis-Related Group 
Evidence-based medicine 
EDH 
EEG 
Epidural haemorrhage 
Electroencephalography 
EQ-5D EuroQol HRQoL instrument with 5-dimensions 
Fisher Classifies the subarachnoid haemorrhage on a CT scan 
GCS Glasgow Coma Scale 
GOS Glasgow Outcome Scale 
HRQoL 
HUI 
Health-related Quality of Life 
Health Utility Index 
ICA Internal carotid arteries 
ICH Intracerebral haemorrhage 
ICP Intracranial pressure 
ICU Intensive care unit 
IQR Interquartile range 
IVH 
Le 
Intraventricular haemorrhage 
Life expectancy 
MCA Middle carotid artery 
MRI 
NHP 
NICE 
Magnetic resonance imaging 
Nottingham Health Profile 
National Institute of Clinical Excellence (UK) 
NICU Neurointensive care unit 
Q1 25th percentile 
Q3 75th percentile 
QALY Quality-adjusted life year 
QoL 
RCT 
Quality of life 
Randomized controlled trial 
7 
 
SAH Subarachnoid haemorrhage 
SD Standard deviation 
SDH 
SF-36 
Subdural haemorrhage 
Short-Form item survey 
TBI Traumatic brain injury 
TTO Time trade-off 
VAS Visual analogue scale 
WFNS 
WHOQOL 
WPT 
Grading scale of the World Federation of Neurological Surgeons 
World Health Organization Quality of life 
Willingness to pay 
  
  
  
  
  
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8 
 
ABSTRACT 
 
Aims: The overall purpose of this study was to evaluate the health-related quality of 
life (HRQoL) and cost-effectiveness of the treatment of severely, acutely ill 
neurosurgical patients. The majority of the study illnesses and conditions are 
known to have a relatively high mortality or an otherwise poor outcome but, they 
are also known to be highly resource-demanding. Since the economics of health 
care is attracting more and more interest, it will become more important to evaluate 
the cost-effectiveness of treatment so that it can be demonstrated that the resource 
allocation is justified. 
Methods: The patients (n=620) for these four separate studies were treated in the 
Department of Neurosurgery of Helsinki University Central Hospital between 1998 
and 2006. The first of these four studies was a Step-Down Unit study in which we 
evaluated a group of patients (n=346) who underwent a major neurosurgical 
operation and were treated in the neurosurgical intensive care unit (NICU) and, 
due to a poor prognosis, were then discharged from the NICU to the step-down 
unit, still depending on life support devices. The following two studies evaluated 
patients who underwent a decompressive craniectomy (DC) for intractable 
intracranial pressure. The first of these, the DC after SAH study, concerned patients 
(n=42) with subarachnoid haemorrhage (SAH) or other neurological emergencies, 
and the second one, the DC after TBI study, evaluated patients (n=54) with 
traumatic brain injury (TBI). The fourth study, the SAH study (n=178), evaluated 
the long-term outcome, HRQoL and cost-effectiveness of the treatment of the SAH 
patients. 
Results: The mortality in the Step-Down Unit study and both of the DC studies 
was high and moderate in the SAH study, 59%, 53%, 41%, and 24% respectively. 
The median follow-up times were 5, 3, 5.6 and 10.8 years. The health-related 
quality of life was assessed with the EuroQol EQ5D instrument and the median 
HRQoL index was compared to the median index of the Finnish reference 
population (0.85). The indices were 0.71, 0.41, 0.85 and 1.00. The outcome was 
also evaluated on the Glasgow outcome scale (GOS), and 49%, 25%, 69% and 75% 
of the patients achieved a good outcome (GOS 1-2). An important measure of well-
being is the ability to live at home, and 49%, 50%, 78% and 88% of the study 
patients were able to live at home. The direct costs of the neurosurgical treatment 
per quality adjusted life year (QALY) were 2521€, 5000€, 2400€ and 1700€. 
Conclusions: For the total of 620 severely ill neurosurgical patients treated in the 
Helsinki Department of Neurosurgery between 1998 and 2006, we found the 
treatment to be cost-effective, and it resulted in health-related quality of life that 
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varied from acceptable to good when compared to the reference population. We 
found no evidence of unnecessary prolongation of human suffering when death was 
inevitable. The worst state of health-related quality of life did not occur among the 
survivors. In summary, these studies indicate that current healthcare resources are 
utilized cost-effectively to achieve a life that is meaningful. Allocation of healthcare 
resources to the severely ill neurosurgical patients seems to be justified.    
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TIIVISTELMÄ 
 
Tavoite: Tämän tutkimuksen tarkoituksena oli arvioida akuutisti ja vakavasti 
sairaiden, neurokirurgisten potilaiden terveyteen liittyvää elämänlaatua (HRQoL) 
ja hoidon kustannusvaikuttavuutta. Tutkimuksessa potilailla olleisiin sairauksiin 
tiedetään liittyvän suhteellisen korkeaa kuolleisuutta tai muutoin huonoa 
lopputulosta, ja sen lisäksi nämä sairaudet ovat myös hoidollisesti paljon resursseja 
vaativia. Koska terveydenhuollon taloudellinen arviointi kiinnostaa yhä enemmän 
ja enemmän, on tärkeää, että hoitojen kustannusvaikuttavuutta arvioidaan niin, 
että voitaisiin osoittaa, että resurssien suuntaaminen on perusteltua. 
Menetelmät: Näiden neljän erillisen tutkimuksen potilaat (n = 620) hoidettiin 
Helsingin yliopistollisen keskussairaalan Neurokirurgian klinikassa vuosina 1998-
2006. Ensimmäinen tutkimus, Tarkkailupotilas-tutkimus (n=346) arvioi 
potilasryhmää, joille oli tehty merkittävä neurokirurginen leikkaus, joita hoidettiin 
neurokirurgisella teho-osastolla (NICU), mutta huonon ennusteen vuoksi siirrettiin 
teholta pois, vaikka potilaat olivat kuitenkin edelleen hengityskoneessa. Seuraavat 
kaksi tutkimusta käsittelivät potilaita, joille tehtiin dekompressiivinen kraniektomia 
(DK) hallitsemattoman kallonsisäisen paineen vuoksi. Ensimmäisessä, DK SAV:n 
jälkeen -tutkimuksessa potilailla (n=42) oli subaraknoidaalinen verenvuoto (SAV) tai 
jokin muu neurologinen hätätilanne ja toisen DK trauman jälkeen -tutkimuksen 
potilaat (n=54) olivat saaneet traumaattisen aivovamman. Neljännessä, SAV-
tutkimuksessa (n=178) arvioitiin SAV-potilaiden pitkän aikavälin tuloksia, 
elämänlaatua ja kustannustehokkuutta. 
Tulokset: Kuolleisuus Tarkkailupotilas- ja DK-tutkimuksissa oli korkea ja SAV-
tutkimuksessa kohtalainen (59%, 53%, 41% ja 24%). Seuranta-ajan mediaani oli 5, 
3, 5.6 and 10.8 vuotta. Terveyteen liittyvä elämänlaatu arvioitiin EuroQol EQ5D –
instrumentilla, josta laskettiin indeksi elämänlaadulle. Tätä verrattiin suomalaisen 
normaaliväestön  indeksiin (0,85). Indeksit olivat 0,71, 0,41, 0,85 ja 1,00. 
Lopputulokset arvioitiin myös Glasgow Outcome -asteikolla (GOS) ja 49%, 25%, 
69% ja 75% potilaista saavutti hyvän lopputuloksen (GOS 1-2). Yksi hyvinvoinnin 
tärkeä indikaattori on mahdollisuus asua omassa kodissa ja 49%, 50%, 78% ja 88% 
tutkimuksen potilaista pystyivät asumaan kotona. Neurokirurgisen hoidon suorat 
kustannukset laatupainoitettua elinvuotta (QALY) kohti on olivat 2521€, 5000€, 
2400€ ja 1700€. 
Johtopäätökset: Näiden 620 vaikeasti sairaan neurokirurgisen potilaan, jotka 
hoidettiin neurokirurgian klinikassa vuosina 1998-2006, hoidon arvioitiin olevan 
kustannusvaikuttavaa ja heidän terveyteen liittyvä elämänlaatunsa vaihteli 
hyväksyttävästä hyvään verrattuna normaaliväestöön. Emme löytäneet todisteita 
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tarpeettomasta inhimillisten kärsimyksien pitkittämisestä silloin, kun kuolema oli 
väistämätön. Myöskään tutkimuksessa kenelläkään eloonjääneistä ei ollut 
huonointa mahdollista terveyteen liittyvää elämänlaatua. Terveydenhuollon 
resurssien kohdentaminen akuutisti ja vakavasti sairaille neurokirurgisille potilaille 
näyttää olevan perusteltua. 
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INTRODUCTION 
 
The basic question in an economic evaluation of health services is whether the 
accomplishment achieved by medical intervention is worth the money spent on it. 
This question can be further divided into two parts: Is the medical intervention 
effective in ordinary circumstances working, and at what costs? The requirement for 
evaluation rises from the fact that resources are limited also in the field of medicine. 
Economic evaluation is becoming more and more important because several factors 
contribute to the increasing costs of health care. The population is aging and the 
number of people with chronic diseases is increasing. The development of 
technology and the pharmaceutical industry provides increasingly more possible 
treatments but also raises the costs of health care. Medicalization, in which human 
conditions or problems are defined and treated as medical conditions, also raises 
the costs.  
Evaluation is required from health care administrators as well as from anyone who 
plans, provides or pays for health care. The question is not only whether to offer a 
particular treatment or not, but extensive consideration is needed on how to 
allocate the limited resources in a way that the largest amount of health is achieved.  
The next question is: When should evaluation be executed? On rare occasions, 
there is a need to evaluate existing treatments that have proved their efficacy and 
effectiveness over the years. The demand for evaluation rises when new treatments 
or drugs are considered. Also objectives, benefits, costs, and potential adverse 
effects of population screening programs should be subject for evaluation. Further, 
a difference between two or more treatments could be a target of evaluation. The 
uttermost case of an evaluation is whether to treat or not, which arises when 
treating the most severely ill patients and when the prognosis of the treatment is 
unclear.  
This area of research is continuously gaining more interest; the number of studies is 
exponentially rising. Studies are conducted by clinicians, medical researchers, 
economists, etc. How can effectiveness be measured in medicine? Traditionally 
medical studies often deal with measurable quantities such as survival, disease-free 
time or laboratory results. In health economic evaluation, both quantity and quality 
of life is assessed and compared to the costs. For this purpose, the concept of 
health-related quality of life was developed and several different approaches have 
been developed to convert it to a numerical value. The concept of a quality-adjusted 
life year (QALY) is a numerical value which includes both the estimation of “how 
good” and “how long”. When medical costs of an intervention in question are 
estimated, the cost of a QALY can be calculated. By using a numeric value for 
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intervention, interventions and health services may become comparable with each 
other and forward information to resource allocation.  
Neurosurgery is a highly resource-demanding field of medicine. Treatment is 
performed by highly specialized professionals, which refers not only to the surgeons 
but the entire treatment team. A lot of high technology and equipment is utilized, 
and neurosurgical intensive care is among the most expensive treatment units. 
Severely ill patients may need prolonged ventilator support and hospital periods are 
longer compared to many other diseases. Recovery time is also in many cases 
prolonged, and many neurosurgical illnesses, even when treated, lead to severe 
morbidity, loss of capability to work and independency.  
Increasingly greater numbers of economic evaluation studies of neurosurgical 
illnesses have been published, but the majority of such publications concern elective 
surgery, such as spinal surgery. Many studies compare different treatment 
techniques or screening methods of certain diseases. However, the quality of life or 
cost-effectiveness of the treatment for acutely and severely ill neurosurgical patients 
is an almost unexamined field. When treating these patients, it may not be easy to 
determine whether the patients will benefit from the resource-demanding treatment 
and there may be a fear that the treatment will lead to an unwanted outcome, such 
as death or an unacceptably poor quality of life. Therefore, the aim of this study 
was to perform a long-term evaluation of the health-related quality of life of acutely 
and severely ill neurosurgical patients and calculate the cost-effectiveness of the 
treatment. 
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REVIEW OF THE LITERATURE 
 
ECONOMIC EVALUATION 
 
The basic economic problem has been sometimes summarized into one sentence: 
How to best satisfy unlimited wants with limited resources (Mike Moffatt, a 
Canadian economist). The most quoted definition of an economic evaluation is: 
‘the comparative analysis of alternative courses of action in terms of both their costs 
and consequences’ by Drummond [Drummond 2005]. The objective of a health 
economist is to evaluate, measure, and compare the costs and consequences of a 
particular medical intervention. 
The evaluation is needed in order to show that what we do is not only subjectively 
important, but it “is working” and it “is worth it”. In medicine, different groups of 
patients compete on resources, and in the larger view, the whole health care system 
competes on resources with other areas such as education or national defence. 
Evaluation is even more important in cases where what we do is “not working” and 
is “not worth it”. The lost resources are also lost benefits of another program which 
could have been cost-effective [Cunningham 2001].  
The number of conducted cost-effectiveness analyses is constantly increasing 
(Figure 1.). While in the 1970s and 1980s the economics of health care was an 
almost unexamined field, in the 1990s the subject started to gain interest. In the 
2000s, economic evaluation became more of a requirement than an object of 
interest. The evaluation of health care programs can be subdivided into different 
types of analysis: Cost-minimization analysis, cost-effectiveness analysis, cost-
utility analysis and cost-benefit analysis (Table 1.). 
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Figure 1. Number of cost-effectiveness publications per year. (Source: Center for the 
Evaluation of Value and Risk in Health. The Cost-Effectiveness Analysis Registry 
[www.cearegistry.org], reprinted with permission) 
 
Table 1. Types of economic evaluation 
 
Analysis Cost-
minimization 
analysis 
Cost-
effectiveness 
analysis 
Cost-utility 
analysis 
Cost-benefit 
analysis 
Abbrevia- 
tion 
 
CMA CEA CUA CBA 
Method of 
analysis 
Analysis in which 
two or more 
interventions of 
the same 
effectiveness are 
compared in net 
costs. 
Analysis in which 
costs and benefits 
of intervention 
are assessed in 
monetary and 
non-monetary 
units 
Subdivision of 
CEA, in which 
costs are assessed 
in monetary units 
and the benefits 
are measured as 
QALYs 
Measures all the 
positive 
(beneficial) and 
negative (costly) 
consequences of 
an intervention or 
program in 
monetary terms. 
Question 
 
Which is the 
cheapest 
intervention? 
What is gained or 
what is avoided 
by an intervention 
and at what costs? 
What is the price 
of a QALY 
gained? 
What is the cost 
intervention in 
relation to 
monetary 
savings?   
Answer An intervention Cost and benefits Costs per QALY Total costs of a 
program? 
Unit of 
outcome 
Monetary Monetary and 
non-monetary 
Monetary and 
non-monetary 
Monetary 
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COST-MINIMIZATION ANALYSIS 
 
Cost-minimization (CMA) analysis is an economic comparison of two or more 
medical interventions in order to find the least expensive. This type of analysis 
expects that the interventions as well as the outcome are clinically equivalent and 
the research is aimed at solely the costs. Although on the surface CMA appears to 
be the most straightforward of the four common types of economic analysis, careful 
consideration must be given to the first critical steps of determining the therapeutic 
equivalence of the interventions. Publications that use CMA are less common than 
other three types of economic studies. One theory for the small number of CMA 
publications is that the researchers are reluctant to claim that a new intervention is 
no better than the existing option [Newby 2003]. 
 
COST-EFFECTIVENESS ANALYSIS 
 
Cost-effectiveness analysis (CEA) is a form of full economic evaluation where both 
the costs and the consequences are examined. The main ideology of CEA is not to 
identify programs that will save money for a system or a provider, although this 
may be the ultimate result, but its aim is to get the most benefits from each 
additional health care euro or dollar expended. Though the basic idea of CEA is 
valid, the limits are the underlying measures of cost and outcomes. The methods in 
use vary considerably while making these assessments. There are standards for cost-
effectiveness study methods, but at times the standards are quite difficult to meet, 
although the compromises may be scientifically entirely legitimate [Gold 1996]. 
  
COST-UTILITY ANALYSIS 
 
Cost-utility analysis (CUA) follows the same principle as CEA, in fact, it could be 
considered a form of CEA [Drummond 2005]. In CUA analyses as well, the costs 
and outcomes and the cost evaluation follow the same principle as in CEA. The 
outcome measure is more structured in CUA. The term “Quality adjusted life year” 
(QALY) is presented here and the concept enables arithmetic processing of the 
outcome. QALY takes into account both the quality and quantity of life. Therefore 
much of the appeal of CUA must be attributed to the fact that it uses QALY 
[Richardson 1990]. Quality of life is indisputably relevant to the allocation of 
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resources. The final product of CUA is monetary value, a cost of one QALY 
achieved by an intervention. The concept of CUA enables a comparison of the cost-
effectiveness of the different diseases, treatments or different groups of patients. 
Again, the reliability of the results lies beneath the execution of the cost and 
outcome analysis. 
 
COST-BENEFIT ANALYSIS 
 
The cost-benefit analysis (CBA) is, in theory, the most powerful method of 
economic evaluation [Drummond 2005]. CBA quantifies benefits and indirect costs 
strictly in monetary terms. CBA evaluates whether the benefits of the intervention 
exceed the costs for the society. CBA has significant value in welfare economics. 
The Hicks-Kaldor criterion designates that the gainers from the intervention could, 
in principle, compensate the losers [Gafni 2006]. Further, this concept of net benefit 
is applicable for intersectoral comparisons (e.g. education, social services, national 
defence). 
 
QUALITY-ADJUSTED LIFE YEAR 
 
The concept of “quality-adjusted life year” (QALY) was originally presented in 
1976 by Zeckhauser and Shepard, as they included both the quality and duration of 
life in health outcome measurements [Sassi 2006]. The underlying concept of 
QALY was developed in the late 1960s by economists, operation researchers and 
psychologists, primarily for use in cost-utility analysis (CUA) [Gold 2002]. The 
concept was adopted and advocated by many health economists [Williams 1996]. 
The basic idea of QALY is to take the health-related quality of life (HRQoL) as a 
parameter with which the duration of life is weighted. Perfect health equals 1 and 
death equals 0. The basic equation is 
              
in which Le is life expectancy. The equation shows that the year of perfect health 
equals to 1 QALY and a year in which HRQoL is reduced to half equals to 0.5 
QALY. Some health statuses may be considered to be worse than death and 
therefore HRQoL may have negative scores [Marcan 2001].  
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EVALUATING HEALTH-RELATED QUALITY OF LIFE 
 
Though the basic equation of QALY is quite simple itself, the evaluation of 
HRQoL and also life expectancy (Le) is more challenging. Several methods have 
been developed to evaluate the HRQoL [Gold 2002].  
 
WEIGHTING 
 
Weighting, sometimes referred to as direct elicitation, means that respondents are 
asked to assess a numerical value for their HRQoL between 0 and 1. There are 
several ways to lay out the question.  
1.) In the Time-trade-off (TTO) method, the respondents are asked to choose 
between a longer time in compromised health to a shorter time in perfect 
health.  
 
2.) In the Standard Gamble (SG) method, respondents are asked to choose 
between remaining in a state of ill health for a period of time or choosing a 
medical intervention which has a chance of either restoring them to perfect 
health or killing them. The TTO and SG methods are preferred by many 
economists.  
 
3.) The Visual analogue scale (VAS) has, for instance, a thermometer-looking 
scale in which respondents are asked to mark a point which represents their 
health-related quality of life. This method has been considered to be 
theoretically inferior to SG and TTO because it is a rating task instead of a 
choosing task [Wein 2009]. The method has the advantage of being the 
easiest to ask, but has been considered to be the most subjective. On the 
other hand, also advocates exist [Parkin 2006]. 
 
HEALTH UTILITY INSTRUMENTS 
 
Another way to describe HRQoL is to use health utility instruments. These 
multiattribute instruments can be, for example, a disease-specific evaluating effect 
of a particular disease and thus an important tool for evaluating the effectiveness of 
a particular treatment. More commonly, however, instruments are generic 
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multipurpose instruments which can evaluate HRQoL independently of a disease, 
disability or treatment. These scales are used to determine HRQoL in terms of their 
levels of several attributes. The number of attributes and levels describing the status 
of each attribute vary among the instruments. The underlying theory behind the 
scales varies. The scales have commonly been calibrated by fitting them to 
preference values obtained from a standard population. These reference values have 
been elicited by using one of the weighing methods mentioned before [Hammitt 
2002].  
There are several instruments from which the most suitable one can be selected. 
There is no consensus on which instrument is preferable. The main purpose of the 
instrument is to produce a single index value for QALY calculations. The most 
utilized instruments are EQ-5D [Brooks 1996], SF-36 (RAND-36), NHP, 
WHOQoL-BREF, HUI, and 15D. 
- The Medical Outcomes Study Short-Form item survey (SF-36) is a widely 
used, multi-purpose health survey with 36 questions, which yields an 8-scale 
profile of HRQoL [Ware 1992]. It is suitable for any age, disease, or 
treatment group. The RAND-36 is based on SF-36. The measured health 
dimensions are: Physical functioning, daily routines (physical limitations), 
social functioning, daily routines (emotional limitations), general mental 
health, vitality, pain, and perception of general health. The score range 
varies from 0 to 100. First publications which utilized SF-36 were published 
in 1988. The Finnish version is “RAND SF-36” [Aalto 1995]. 
 
- Nottingham Health Profile (NHP) was developed in 1980 [Hunt 1980]. The 
two-part survey measures subjective physical, emotional, and social aspects 
of health. Part 1 contains 38 questions in six dimensions of health, including 
physical mobility, pain, social isolation, emotional reactions, energy, and 
sleep. Part 2 consists of seven yes/no statements about seven areas of life 
that most reflect the health status. The scoring range is from 0 to 100. 
 
- The World Health Organization Quality of Life (WHOQOL) project was 
initiated in 1991, targeting to develop an international cross-culturally 
comparable quality of life assessment instrument. The WHOQOL-BREF is 
a shorter version of the original instrument and it contains 26 questions 
which measure the physical health, psychological health, social 
relationships, and the environment. The WHOQOL-BREF is sometimes 
considered to be more convenient in large research studies or clinical trials 
[Murphy 2000]. 
 
- The Health Utilities Index (HUI) is a family of generic preference-based 
systems, with the instruments HUI, HUI mark2, and HUI mark3. The 
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health dimensions include vision, hearing, speech, ambulation/mobility, 
pain, dexterity, self-care, emotion and cognition. Each dimension has 3-6 
levels. HUI systems describe almost a million unique health states. 
  
- 15-D is a Finnish questionnaire which consists of 15 questions. The 
development of the 15-D started in the late 1970s and it was originally 
published in a 12-question form [Sintonen 1981]. In 1986, the first 15-
question version was released [Sintonen 1992]. The examined health areas 
are: mobility, vision, hearing, breathing, sleeping, eating, speech, excretion, 
usual activities, mental function, discomfort and symptoms, depression, 
distress, vitality, and sexual activity. There are 5 ordinal levels on each 
dimension. 15-D enables to evaluate the results either in profile mode or it 
can convert answers to a preference-based single index value for HRQoL on 
a 0-1 scale. 15-D is the most widely used instrument in Finland, but the 
questionnaire is also available in 20 languages. 
 
EQ-5D 
 
The EuroQol organization started developing a non-disease-specific multipurpose 
instrument in 1987. EQ-5D was initially developed simultaneously in Dutch, 
English, Finnish, Norwegian and Swedish. The questionnaire is currently being 
translated into 102 languages. It consists of five questions evaluating five 
dimensions of health: mobility, self-care, usual activities, pain or discomfort, and 
anxiety or depression (Figure 2.). In the 3-L version, each question can be answered 
by one of the three following responses: no problems (1), some or moderate 
problems (2), and extreme problems (3). Euroqol has recently also released EQ-5D-
5L, which consists of 5 available levels. In 3the L-version, the answers of five 
questions form a sequence of five numbers (e.g. 11212, Table 2.), which can then be 
converted into the HRQoL index by a EuroQol algorithm which uses reference 
values obtained from the standard population by a weighing method. The reference 
value is elicited with either the TTO or VAS method, and the TTO method based 
references are preferred to use when an economic evaluation is concluded in the 
research. In the EQ-5D system, the HRQoL index value can have negative values, 
as some states of health can be considered worse than death [Marcan 2001]. 
The HRQoL index value can be compared to the values of the reference 
population. The median HRQoL of the reference population is presented in Figure 
3. The value is based on questionnaires of 2411 Finnish residents [Ohinmaa 1996]. 
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Figure 2. EQ-5D questions  
 
 
Figure 3. EQ-5D median reference values of HRQoL based on questionnaires of 
2411 Finnish residents. 
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Table 2. Examples of EQ-5D health state valuations 
Health state 
 
 
 
Description HRQoL  
index value 
11111 no problems walking about 
no problems with self-care 
no problems with usual activities 
no pain 
not anxious or depressed 
 1,00 
12211 no problems walking about 
some problems with self-care 
some problems with usual activities 
no pain 
not anxious or depressed 
 0,78 
22222 some problems walking about 
some problems with self-care 
some problems with usual activities 
some pain 
some anxious or depressed 
 0,52 
33333 confined to bed 
unable to take care of self 
unable to perform usual activities 
extreme pain 
extreme anxious or depressed 
-0,59 
 
 
COSTS ANALYSIS 
 
Evaluating the costs of the intervention is the other central feature of the economic 
evaluation [Drummond 2005]. There have been critical reviews that cost analysis 
had received relatively little attention compared to the evaluation of the benefits. It 
is clear that the economic evaluation consists of two equal components and the 
adequate cost analysis may not be underestimated. Fundamentally, all relevant 
costs should be determined and included in the analysis, but in practice this might 
be challenging. 
In literature, the concept of “direct costs” in this context comprises all medical costs 
of the intervention including treatments, operations, rehabilitation, special 
equipment, in-patient days, and also non-medical costs such as travel expenses, the 
costs of social services, etc. “Indirect costs” arise from an illness but are not 
medically based. They can be costs because of morbidity or premature death, such 
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as loss of productivity. The calculation of the direct costs could be challenging. 
Some aspects should be considered, such as how long the cost should be taken into 
account and what costs should be included in the health care perspective. How 
should capital costs (e.g. hospital buildings, equipment) and overhead costs (e.g. 
laundry, medical records, cleaning) be handled? The indirect costs can be monetary 
and possible to evaluate, such as loss of productivity, or they can be non-monetary, 
such as loss of family leisure time, and therefore the monetary value is harder to 
assess. As a conclusion, the area of the cost analysis is incoherent and demands for 
a more unambiguous and transparent analysis exist, since no amount of statistical 
analysis can compensate for poor quality cost data [Graves 2002]. 
 
DIAGNOSIS-RELATED GROUPS 
 
The costs analysis is a critical step in economic evaluation and unfortunately it is 
also one of the most challenging steps to evaluate precisely. Many attempts have 
been made to elucidate this field, and at present time a system called Diagnosis-
Related Group (DRG) has been utilized widely. It is a statistical classification 
system for hospital cost evaluation. The system estimates costs by dividing patients 
into groups according to their diagnosis. This system was originally developed by 
scientists in Yale University and it was first implemented in New Jersey by a small 
group of hospitals [Fetter 1980]. The DRG system is mainly based upon the 
patient's principal diagnosis, which originally was divided into 467 groups, but also 
other diagnoses, gender, age, sex, treatment procedure, discharge status, and the 
presence of complications or comorbidities are taken into account. The national 
program of implementing DRG in Finnish health care was conducted between 
2008 and 2011. As a result, the DRG system is now been utilized in the majority of 
the hospital districts and the new health care law aims at comprehensive national 
usage of the DRG system. 
EVALUATION OF THE EFFECTIVENESS OF AN INTERVENTION 
 
The QALY calculation and the resulting answer depends on the type of 
intervention in question. QALYs can be calculated for one or several treatments. 
QALYs can be compared as a function of time, and a single patient or patients with 
and without intervention can be compared (incremental QALYs). For a particular 
intervention, QALYs can be calculated by first assessing the QALY amount 
without intervention and then after an intervention. The first QALY amount 
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depends on the health-related quality of life (HRQoL) and the life expectancy / Le) 
before and after. 
QALY(before)=HRQoL(before)*Le(before) 
QALY(after)=HRQoL(after)*Le(after) 
The gained number of QALYs = QALY(after) – QALY(before). 
The same way the incremental value of two different treatments can be calculated, 
the acquired QALYs with separate groups of patients are calculated and compared 
with each other. For example, treatment A costs 1500€ and outcomes 3.6 QALYs, 
and treatment B costs 1000€ and outcomes 1 QALY, the incremental cost is 500€ 
and incremental QALYs are 2.6, which results in 192.31€ per QALY gained. 
These first two measurements are particularly suitable for an evaluation of an 
elective intervention in which patients can be contacted and interviewed 
beforehand. Evaluation of acute illnesses differs from this scenario, as there is no 
way of anticipating these events. HRQoL and Le can be approximated 
retrospectively. For example, QALYs can be used to compare a treatment that has 
a substantial impact on health quality and no effect on life expectancy with a 
different treatment that results in no change in health quality but a longer life 
expectancy (Figures 4. and 5.). 
 
Figure 4. Example case of HRQoL. The X-axis presents time points: T0 is the 
date of birth. T1 is the date of getting ill; the illness affects HRQoL, but not life 
expectancy. The T2 intervention starts. The T3 intervention restores HRQoL 
partially, without intervention HRQoL stays on a lower level. Life continues to 
point T4 with the same level of HRQoL. T5 is the date of death, not related to a 
particular illness. 
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Figure 5. Example case of HRQoL. The X-axis presents time points: T0 is the 
date of birth. T1 is the date of getting ill, a serious illness affects HRQoL and 
life expectancy. The T2 intervention starts. The T3 intervention restores 
HRQoL partially and enhances life expectancy; without intervention patient 
dies. Life continues to point T4 with the same level of HRQoL. T5 is the date of 
death, could be related to a particular illness. 
 
COST-EFFECTIVENESS THRESHOLD 
 
The next step of the evaluation process is a calculation of the cost of one QALY 
achieved by intervention. Once we have an explicit number of QALYs and the total 
sum of costs to produce these QALYs, we can calculate the cost per QALY by 
dividing costs by QALYs. This monetary value of QALY can then be used in 
several ways. The costs can be compared with each other regardless of the 
heterogeneity of the patients, illnesses, treatment, or medical programs.  
In order to determine whether the intervention is cost-effective, there has to be an 
established threshold with which a value can be compared. This value is a price of 
how much society should be prepared to pay for a QALY. There is no exact 
consensus on the price, but a commonly cited number is US is $50 000. According 
to Grosse [Grosse 2008], there was over 500 CEA studies published and in half of 
them the threshold of the cost of one QALY was set to $50 000. Although there are 
no theoretical bases for that specific figure, it has been widely referred in 
publications as ‘generally accepted’, ‘commonly cited’ or ‘an established practice’. 
The history of the $50 000 threshold is not well established, but it first appeared in 
the late 1980s in studies of end stage renal failure and it was associated with CE 
evaluations of dialysis. Since the 1990s it has been adopted as a main figure of CEA 
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studies. This figure has also raised criticism due to the lack of theoretical or 
empirical justification, and it has also been considered to be outdated. The criticism 
is well founded, as the same figure has been referred to already in the 1940s. The 
usual range of the CEA threshold is from $20 000 to $100 000 [Kaplan 1982, 
Laupacis 1992]. In the UK, the National Institute for Clinical Excellence (NICE) 
does not present strict decision rules, the cost of a QALY being acceptable when 
ranging between £20,000-30,000 [Rawlins 2004].  
The uttermost question is where these figures eventually originate from. 
Willingness to pay (WTP) for one QALY is the cardinal utility measure. In the end, 
people are in charge of which costs are covered by common funds. However, the 
WTP for QALY is not simple to define. There is a lack of evidence of a constant 
value of WTP for a QALY. In particular, there is evidence that the average 
individual WTP for QALY is lower when it results from improvements in health 
status from relatively minor conditions than the WTP for QALYs gained from life-
saving interventions [Gyrd-Hansen 2003].  
One adverse aspect of the widespread use of CE thresholds, such as 
$50,000/QALY in the USA or £30,000/QALY in the UK, is that it might also 
contribute to the rise of healthcare costs by encouraging the coverage of costly new 
therapies, especially pharmaceuticals [Gafni 2006]. Thresholds and especially the 
upper boundaries of the CE range might work as a target toward which the costs of 
new treatments are customized.  
 
COMPARATIVE EFFECTIVENESS RESEARCH 
 
The concept of “Comparative effectiveness research” was defined by the US 
Committee on Comparative Effectiveness Research Prioritization of the Institute of 
Medicine in 2009 [Committee 2009]. The term Comparative effectiveness research 
(CER) gathers the methods and technologies of the economic evaluation, health-
related quality of life and effectiveness of the treatment under one field of research. 
The Institute of Medicine’s committee has defined CER as "the generation and 
synthesis of evidence that compares the benefits and harms of alternative methods 
to prevent, diagnose, treat, and monitor a clinical condition or to improve the 
delivery of care. The purpose of CER is to assist consumers, clinicians, purchasers, 
and policy makers to make informed decisions that will improve health care at both 
the individual and population levels" [Committee 2009]. 
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EVALUATION OF NEUROSURGICAL TREATMENTS 
 
While the numbers of economic evaluations and CER studies are constantly 
increasing in other fields of medicine, in neurosurgery the use of CER methodology 
and economic evaluation overall remains in its infancy [Marko 2012]. The 
American Association of Neurological Surgeons, AANS/CNS Guidelines 
Committee has expressed concern about the lack of CER studies in neurosurgery 
[Zusman 2010]. The reluctance of the neurosurgical community to conduct CER 
studies is not well understood, since neurosurgery could be considered an optimal 
field for CER [Stein 2012]. The volume of the patients is relatively small, but the 
neurosurgical treatment is highly resource-demanding. There are many existing 
treatments with unanswered questions, but on the other hand there are relatively 
few randomized controlled trials (RCT), since they are difficult to fund, recruit, 
conduct and justify, and this is even more difficult when dealing with acute 
neurosurgical emergency. Partly due to the difficulties in executing traditional 
evidence-based medicine (EBM) with RCTs, there are more and more advocates for 
CER studies. In 2012, an expert panel in TBI pointed out that randomized 
controlled trials have not led to any identifiable major advances. The rigorous 
protocols and tightly selected populations of the RCT studies make the results 
difficult to generalize, and therefore the panel suggested that future research could 
concentrate on comparative effectiveness studies [Maas 2012].  
 
COST-EFFECTIVENESS STUDIES OF ACUTE NEUROSURGICAL 
ILLNESSES 
 
NEUROSURGICAL INTENSIVE CARE UNIT 
 
Over the past decades, intensive care units have specialized to focus on care for e.g. 
trauma, cardiac and post-surgical care as well as stroke units and neonatal and 
neurosurgical care. Care in these specialized units is often provided by physicians 
within those specialties and dedicated nurses who have additional training in those 
areas [Diringer 2001]. Neurosurgical ICU is highly specialized in monitoring and 
treating intracranial pressure. Though the field is less studied, there is evidence that 
the outcome of neurosurgical patients treated in the NICU have a better outcome 
and lower mortality than patients treated in the general ICU [Mirski 2001, Diringer 
2001]. The treatment in any ICU is expensive, but treatment in these specialized 
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ICUs is even more resource-demanding. In order to be cost-effective, the NICU 
treatment has to target the resources correctly, which basically means selecting the 
patients correctly.  
A proper patient policy includes selecting patients on admission, according to who 
will most likely benefit from the treatment, and on the other hand withdrawal of the 
treatment when the patient is not considered to benefit from the treatment any 
longer. The difficulty is to identify these patients at the earliest opportunity. When 
the clinical condition of the patient is taking a course towards a hopeless situation, 
the decision of the withdrawal of the treatment should be done. Futile treatment 
periods should be limited to the minimum in order to retain the cost-effectiveness of 
the ICU treatment and to ensure a consensus on the willingness to pay for extended 
treatments in the ICU. The literature search on NICU patients’ QoL or the cost-
effectiveness of the treatment yielded no published studies. 
 
TRAUMATIC BRAIN INJURY 
 
Traumatic brain injury (TBI) is a common cause of death and disability and it often 
involves young persons. The prevalence of TBI in Finland in 1990-2000 was 
1/1000, which means approximately 15 000 to 20 000 new TBIs each year [Käypä 
hoito -suositus, Aivovammat]. Half of the TBIs occur in the age group of 15 to 34 
years, and when it leads to permanent disability of a young person, the economic 
burden is enormous. Worldwide, TBIs cause the largest number of disability-
adjusted life years lost, which includes both years lost to death and to varying 
degrees of disability [Ghajar 2000]. The majority of TBIs arise from motor vehicle 
accidents, falls, violence and a large portion of injuries in Finland is associated with 
alcohol abuse.  
TBIs are graded as mild, moderate and severe injuries, and the evaluation of the 
severity of the injury is often conducted by using the Glasgow coma scale: mild 
GCS 13-15, moderate GCS 9-12 and severe GCS 3-8 [Ghajar 2000]. TBIs are 
usually divided into primary and secondary injuries. A primary injury is caused by 
the original insult and it may be a penetrating or closed injury. It may cause a 
fracture of the skull, a concussion, a cerebral laceration or contusion, haemorrhages 
(subarachnoid, subdural, epidural or unspecified intracranial haemorrhage) or nerve 
damage (diffuse axonal injury). The first insult leads to secondary brain damage, 
which is damage that evolves over time after the trauma, and may include: brain 
oedema and lead to increased intracranial pressure. Other common consequences 
are: Epilepsy, intracranial infection, abnormalities of the cerebrospinal fluid cycle, 
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haemodynamical instabilities, other infections (also treatment related), abnormal 
blood coagulation, metabolic, hormonal and nutritional disorders.  
The diagnostics of the injury may begin at the injury site by an evaluation of the 
GCS and may include, for instance, computerized tomography (CT), CT 
angiography, magnetic resonance imaging (MRI), electro-encephalogram (EEG), 
and measurement of intracranial pressure. The treatment of severe TBI usually is, 
and should be, centralized in specialized units. Treatment consists of pre-hospital 
care, operational treatment (e.g. hematoma evacuation, repairing skull fractures, 
decompressive craniectomy), medical treatment (anaesthesia, seizure prevention, 
metabolic and cardiovascular stabilizing drugs) physiological and psychological 
rehabilitation. The treatment is highly resource-demanding and specialists of 
multiple fields are required; neurosurgeons, neuroanaesthesiologists, specially 
trained nursing staff for treatment and rehabilitation and various therapists (speech, 
physical, occupational). 
Even though TBIs are common, they usually affect young and “profitable” citizens, 
and the economic burden is enormous (including expensive treatments and loss of 
QALYs), the actual QALY studies of TBI are quite rare. The literature search from 
PubMed with the combination of “Traumatic brain injury” and “QALY” returned 
a total of 19 published studies. Of these 19 papers, two are partial works of the 
present research (DC after SAH study and DC after TBI study). Despite the 
keywords, the QALYs and cost-effectiveness were calculated only in a few of these 
studies. The first published studies estimated the methods of assessing the quality of 
life of neurological and TBI patients [Riemsma 2001, von Steinbuechel 2005]. A 
few publications study the economic burden of neurological diseases. Olesen et al. 
studied the economic burden in Europe [Olesen 2003], Haagsma et al. estimated 
the burden of non-fatal injuries by calculating disability-adjusted life years. They 
concluded that the burden of years lived with disability with TBI patients is 
underestimated by ignoring temporary health consequences [Haagsma 2008]. Levi 
et al. studied the burden of occupational injuries in Italy [Levi 2011]. Norum el al. 
estimated non-proven intensive treatments and rehabilitation of the TBI in Norway 
and calculated QALYs, and they found that the cost of a QALY was unacceptably 
high in these experimental treatments and TBI treatment should use evidence-based 
methods [Norum 2012]. Tilford et al. studied paediatric TBI and the cost-
effectiveness of treatment and technology [Tilford 2007(7) and 2007 (12)]. A few 
studies dealt with diagnostic strategies and their cost-effectiveness [Stein 2006, 
Dunham 2011, Holmes 2012]. Ryynänen et al. also included severe TBI patients in 
their literature review of the level of pre-hospital care. They also compared the 
advanced and basic level of pre-hospital care in terms of quality of life and cost-
effectiveness, but the comparison turned out to be challenging. The pre-hospital 
care given by emergency medicine experts might be good, but given by paramedics 
it might even be harmful (e.g. intubation without anaesthesia) [Ryynänen 2010]. 
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Galvagno et al. also conducted a literature review of pre-hospital care and 
helicopter use in trauma and also in severe TBI. However, no studies were found to 
evaluate the secondary outcome of morbidity as assessed by QALYs and DALYs 
[Galvagno 2013]. Cotton et al. performed a cost-utility analysis of levetiracetam 
and phenytoin for posttraumatic seizure prophylaxis, which revealed the superiority 
of phenytoin [Cotton 2011]. Three studies of TBI and decompressive craniectomy 
have been published [Ho 2011, Whitmore 2012 and Honeybul 2012]. These are 
discussed further in the next section.  
 
DECOMPRESSIVE CRANIECTOMY 
 
Decompressive craniectomy (DC) is an extreme treatment for a malignant increase 
of the intracranial pressure (ICP). In DC, a large piece of the skull is removed in 
order to enlarge the space for oedematous brain and therefore lower the ICP. Brain 
oedema is usually due to a primary insult, in which underlying causes might be 
traumatic brain injury (TBI), ischemic strokes, intracerebral haemorrhage, 
infection, tumour, a demyelinating process or a systemic condition (e.g. electrolyte 
imbalance, diabetic ketoacidosis). The conservative treatment methods include, for 
example, administration of hypertonic fluids, mannitol infusions, mild 
hyperventilation, sedation and hypothermia [Sahuquillo 2006]. When ICP is not 
responding to either maximum conservative treatment or drainage of cerebrospinal 
fluid via a ventriculostomy, there is no other treatment than enlarge the space to 
lower ICP.  
The concept of DC is, in fact, over a hundred years old [Kakar 2009] and in 1902 
Emil Kocher, the first Swiss neurosurgeon stated that “if there is no CSF pressure, 
but brain pressure exists, then a pressure relief must be achieved by opening the 
skull” [Hutchinsson 2011]. The DC procedure gained success in the early 1970s, 
until publications showed a poor outcome of DC patients and DC was abandoned 
until the 1990s [Tagliaferri 2012]. In 1999, Guerra et al. published the results of a 
20-year period of utilizing DC. His good results lead to the rediscovery of DC in 
intractable ICP management [Guerra 1999]. Since 2000, DC has been gaining 
popularity and the number of publications is increasing steadily.  
DC is a perfect example of such neurosurgical treatment referred in previous 
paragraph. It has been utilized for a long time, but no RCTs have been conducted 
until 2010. Case studies and retrospective series of DC patients were published, 
presenting various conclusions. The immediate effect of a craniectomy in lowering 
the intracranial pressure is well recognized [Daboussi 2009, Timofeev 2008], but 
the effect on the patient’s long-term outcome has been controversial. A number of 
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publications have cautiously taken a stand in either direction, on behalf of DC or 
against it. The most common conclusion has been that there is a need for 
randomized studies [Hutchinsson 2007, Kakar 2009, Sahaquillo 2006, Morgalla 
2008, Daboussi 2009, Danish 2009, Lemcke 2010, Howard 2008]. DC is utilized 
the most after TBI. It has been shown that children benefit from DC after TBI 
[Appelboom 2011], and for adults many reports have been very encouraging 
[Sahaquillo 2006]. Reports of small series or case reports also exist on DC as being 
useful with a malignant MCA infarction with restriction [Arac 2009, Vahedi 2007]. 
DC has also been found to be useful and resulting in a good outcome in some 
neurological emergencies with intractable ICP, such as encephalitis [Adamo 2008, 
Pérez-Bovet 2012], toxoplasmosis [Agrawal 2005], sinus thrombosis [Ferro 2011], 
SAH [Gueresir 2009, Schirmer 2009] and demyelinating disease [Ahmed 2010, 
Nilsson 2009].  
There are some studies on the long-term outcome of DC after TBI [Timofeev 2008, 
Danish 2009, Morgalla 2008, Lemcke 2010, Howard 2008, Meier 2000, Pompucci 
2007, Harrison-Felix 2009], but only few have evaluated the health-related quality 
of life. Until 2010, not a single DC study has been published evaluating the cost-
effectiveness of the treatment.  
The first randomized multicentre DC study, DECRA, was highly expected. The 
study group published their results in NEJM in April 2011 and the conclusion was: 
“In adults with severe diffuse traumatic brain injury and refractory intracranial 
hypertension, early bifrontotemporoparietal decompressive craniectomy decreased 
intracranial pressure and the length of stay in the ICU but was associated with more 
unfavourable outcomes” [Cooper 2011]. Instead of offering clarifying aspects of the 
outcome and indications of DC, the results of DECRA have been rather confusing. 
The study setup has raised a lot of criticism and the generalization of the results is 
not evident [Hutchinson 2011, Torres 2012]. This might have affected the statement 
of the TBI panel to favour CER studies over the RCTs.  
The literature search from PubMed with a combination of “Decompressive 
craniectomy” and “QALY” returned a total of 5 published studies. Of these 5 
papers, two are partial works of the present research. In 2011, Ho el al. published a 
study of 168 Australian TBI patients who underwent DC. In their study, the 
average cost per QALY was high (US$682,000), and therefore they concluded that 
DC was not cost-effective for patients with extremely severe TBI [Ho 2011]. 
Whitmore et al. presented opposite conclusions in their study in 2012. They found 
that when all the costs of severe TBI are considered, aggressive treatment (meaning 
invasive ICP measuring and DC) is a cost-effective option, even for older patients 
[Whitmore 2012]. Honeybul et al. considered an important ethical aspect of DC in 
their study in 2012. They concluded that DC would appear to have a medical 
indication for carefully selected patients, but they presented the need to develop 
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reliable outcome prediction models for patient selection which would provide an 
objective assessment of the most likely outcome for those patients who require 
decompression [Honeybul 2012].  
The latest review of DC was published by Kolias et al. in June 2013 [Kolias 2013]. 
They reviewed the evidence and presented considerations regarding the surgical 
technique, ethics and the cost-effectiveness of DC. As a conclusion, they presented 
that DC can reduce ICP acutely and decrease the risk of herniation, and most of the 
available evidence for DC comes from studies in TBI and ischemic stroke. As the 
DECRA study failed to provide evidence of the superiority of early (so-called 
“prophylactic”) DC, the ongoing trial (RESCUEicp) is investigating the 
effectiveness of DC as a last tier therapy. 
 
ANEURYSMAL SUBARACHNOID HAEMORRHAGE 
 
Aneurysmal subarachnoid haemorrhage (SAH) is a neurological emergency and 
often a severely disabling disease [Nieuwkamp 2009]. Aneurysmal SAH is the most 
common cause of nontraumatic SAH, which accounts for about 80% of cases. The 
remaining 20% of nontraumatic cases are nonaneurysmal, including 
perimesencephalic subarachnoid haemorrhage, and are associated with a good 
prognosis [Suarez 2006].  
The incidence of SAH varies widely throughout the world. The worldwide 
incidence is estimated to be 9.1. Finland has a high incidence of SAH, 22.7 per 
100 000 [Steiner 2013]. The incidence increases linearly with patient age and the 
median age of onset of the first SAH is 50–60 years. The overall mortality is 
estimated to be 50-60%. It has been estimated that 10-15% of the patients die before 
ever reaching the hospital and that out of all concerned, 25% die within 24 hours 
from the insult with or without medical treatment. Of the hospitalized patients, 
40% die within a month, and within 6 months the total mortality of all patients rises 
to over 50% and approximately one third of the survivors need lifelong care [Suarez 
2006]. Even if a patient is still alive one year after SAH, it has been demonstrated 
that survivors have excess mortality, which is attributed to an exceptional risk of 
deadly cerebrovascular events [Korja 2013].  
In aneurysmal SAH, three variables are the most closely related to the outcome: the 
neurological condition of the patient on admission, age, and the amount of 
extravasated blood seen on CT scans [Steiner 2013]. The other prognostic factors 
are occurrence of rebleeding, appearance of cerebral vasospasm, co-morbidities, a 
history of smoking and the location of the aneurysm [Rosengart 2007]. The 
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diagnostics of the SAH includes a CT scan, in which SAH is almost always 
detectable one day after SAH. CT angiography or digital subtraction angiography 
(DSA) are used to locate the aneurysm. MRI can detect SAH weeks after the 
original bleed, and normal cerebrospinal fluid excludes SAH within the last 2–3 
weeks [Steiner 2012]. 
The treatment protocol usually involves early occlusion of the aneurysm by surgical 
clipping or endovascular coiling [Withfield 2001]. This reduces the risk of rebleed, 
which is associated with high mortality and morbidity. After that, the treatment is 
targeted to prevent and/or treat the complications. Other than rebleeding, cerebral 
vasospasm is the leading cause of morbidity and mortality following aneurysmal 
SAH. While angiographic vasospasm, typically observed between 5 and 14 days, 
may occur in up to 70% of patients, symptomatic vasospasm may only occur in 
about 30% of patients [Velat 2011]. Spasm is generally treated by so-called triple-H 
therapy (hypervolemia, hypertension, haemodilution) and a calcium antagonist. 
Other complications, such as hydrocephalus and seizures, may require treatment 
[Bederson 2000]. Hydrocephalus occurs in approximately 20% of patients during 
the acute phase and in about 10% during the chronic phase after SAH [Steiner 
2012]. Acute phase treatment is a complex combination of surgical, intensive care 
and medical treatment. 
The recovery may be slow and require extensive rehabilitation. The long-term 
recovery and prognosis depend on the severity of the initial haemorrhage and the 
number and severity of the complications. A high proportion of long-term survivors 
of SAH experience ongoing deficits in high level (neuropsychological) functioning. 
These deficits result in impairment in social roles [Hackett 2000]. 
The importance of assessing the health-related quality of life (HRQoL) has also 
yielded studies of SAH patients’ HRQoL within the last few years [Ronne-
Engström 2011, Leach 2011, Wong 2011, Meyer 2010, Al-Khindi 2010]. The 
literature search from PubMed with the combination of “Subarachnoid 
haemorrhage” and “QALY” returned a total of 20 published studies in English. Of 
these 20 papers, two are partial works of the present research. The cost-effectiveness 
of the diagnostic strategies was evaluated in five publications [Jethwa 2013, Ward 
2012, Sanelli 2009, Kallmes 1997, Tolias 1996]. Eight of these publications 
evaluated the cost-effectiveness of screening and treating asymptomatic aneurysms 
[Bor 2010, Wermer 2008, Takao 2008, Wermer 2004, Brown 2004, Johnson 1999, 
King 1995, Gaetani 1998]. Bardach el al. studied the cost-effectiveness 
regionalization of SAH treatment [Bardach 2004]. Koffijberg et al. performed a 
cost-utility analysis of aneurysm occlusion in elderly patients [Koffijberg 2011]. 
D'Ambrosio et al. evaluated the clinical outcome and quality of life of patients with 
decompressive hemicraniectomy for poor-grade aneurysmal SAH [D'Ambrosio 
2005] Comparative studies of treatments of surgical clipping or endovascular 
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coiling of aneurysm have been published [Zubair 2009, Takao 2008]. The economic 
burden of SAH in the UK has been evaluated [Rivero-Arias 2010]. Predictors of a 
good or poor outcome have been determined [Hütter 2000].  
 
OTHER ACUTE ILLNESSES AND COST-EFFECTIVENESS 
 
Altogether, there are very few published studies of the HRQoL, QALY or cost-
effectiveness of the treatment of acute neurosurgical illnesses. A literature search in 
PubMed with “QALY” and “epidural or subdural hematoma” yielded no results. 
“Intracerebral haemorrhage” and “QALY” yielded 8 publications and half of them 
estimated anticoagulation drugs. The most recent publication on the cost-
effectiveness of surgical decompression for space-occupying hemispheric infarction 
by Hofmeijer et al. was published in Stroke in August 2013 [Hofmeijer 2013]. They 
randomized 39 patients with middle cerebral artery infarction into two groups; 
surgical compression and medical treatment groups. After 3 years, 24% of the 
surgical patients and 78% the medical patients had died. They found that the 
surgical group had more QALYs but at high costs.   
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AIMS OF THE PRESENT STUDY 
 
The overall purpose of this study was to evaluate the health-related quality of life 
and the cost-effectiveness and cost-utility of the treatment of severely, acutely ill 
neurosurgical patients. The majority of the study illnesses and conditions are 
known to have relatively high mortality or have an otherwise poor outcome, but on 
the other hand they are also known to be highly resource-demanding. While the 
economics of the health care is gaining more and more interest, there is a demand 
to evaluate the cost-effectiveness of the treatment and a further need to demonstrate 
that the resource allocation is justified.  
1. One of the main challenges of a neurosurgical intensive care unit (NICU) is the 
end-of-life decision making and restriction of the treatment. When the patient is 
not considered to benefit from NICU treatment because of a poor prognosis, 
one way to manage it, is to disconnect patients from life-supporting devices. 
Previously, the policy in the Department of Neurosurgery in Helsinki was to 
remove patients from the highly resource-demanding NICU to the common 
hospital wards with respirators. Therefore, despite the poor prognosis, they were 
given more time for the recovery. The purpose of the Step-Down Unit study was 
to evaluate the outcome of this seriously ill group of patients. Was the previous 
policy just extension of humane suffering or was the treatment clinically 
justified? Further, the cost-effectiveness (CE) of the treatment was evaluated. 
 
2. Decompressive craniectomy (DC) is one of the most extreme treatments in 
medicine. When all conservative means to handle intracranial pressure fail, a 
large piece of bone is removed from the skull in order to expand the space for 
injured or affected brain, as the oedema of the brain is elevating the intracranial 
pressure and threatens to damage the brain permanently. The purpose of the 
DC after SAH study was to evaluate the outcome and the health-related quality 
of life (HRQoL) of the patients who underwent DC because of SAH or other 
neurological emergency. The purpose was also to conduct the first cost-
effectiveness evaluation of the DC treatment. 
 
3. The purpose of the DC after TBI study was to evaluate the poor grade TBI 
patients who underwent DC. The study group consisted of patients who 
suffered severe TBI with hematoma, contusion or diffuse brain injury. The 
trauma led to elevated intracranial pressure, which was untreatable despite the 
maximum conservative treatment in the NICU. As a last possible treatment, a 
surgical enlargement of the space for swollen brains was conducted. As the 
previous literature on the advantages of DC remains contradictory, our aim was 
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to study the outcome of this group of patients, and the main goal was to execute 
the first cost-effectiveness study of DC after TBI. 
 
4. The subarachnoid haemorrhage (SAH) is one of the most dramatic and 
devastating acute conditions. It is associated with high mortality and morbidity. 
Although an increasing number of HRQoL studies of SAH patients are being 
published, long-term studies do not exist. SAH is fairly common in Finland and 
the long-term outcome of the patients is a subject of special interest. Our 
previous studies implicated that the recovery of neurosurgical patients took a lot 
longer than generally was expected in the literature; therefore our purpose was 
to examine the outcome of SAH patients after ten years from the original 
bleeding.  
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MATERIALS AND METHODS 
 
Patients for these four studies were treated in the Department of Neurosurgery of 
Helsinki University Central Hospital, which is the only neurosurgical unit in 
Southern Finland and serves a population of almost 2 million. More than 3100 
operations are performed each year. All of these studies were approved by the ethics 
committee of the Helsinki and Uusimaa Hospital District. 
 
PATIENT SELECTION FOR THE STEP-DOWN UNIT STUDY 
 
The Quality of Life after Neurosurgical Disease and Treatment study began on 
April 1, 2000 at our institution. Every patient admitted to the neurosurgical clinic 
between May 2000 and January 2003 was asked by a study nurse to participate in 
this study. Only those admitted for spinal surgery were excluded. During this 33-
month study period, 6959 patients were admitted to our institution and a total of 
3637 (52%) patients entered the program. Consent for study participation came 
either from the patient or from next-of-kin. Of the total of 6959 patients, 5367 were 
at some point treated in the intensive care unit (ICU) (Figure 6.). For the Step-
Down Unit study, the patients were selected by the following criteria: 1) Patients 
were first treated in the ICU. 2) The treatment period in the ICU of patients in poor 
condition was prolonged 3) A multidisciplinary assessment evaluated that there is 
no improvement in the prospect in ICU care despite the need for ventilator support. 
4) Patients were transferred to a step-down unit. Of the ICU patients, 478 met the 
enrolment criteria. Consent was available from 346 patients, who then joined this 
study. The underlying diagnosis of the patients of the Step-Down Unit study were 
SAH (21%), intracerebral haemorrhage (ICH,16%), acute or chronic subdural 
hematoma (SDH, 25%), TBI or epidural hematoma (25%), and primary 
intracranial tumour (benign, malignant)(5%). 
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Figure 6. Patient selection for the Step-Down Unit study. 
 
PATIENT SELECTION FOR THE DC STUDIES 
 
The DC after SAH and DC after TBI studies involved an evaluation of the outcome 
and cost-effectiveness of decompressive craniectomy. The patients for these two 
studies were treated in our institute in 2000 - 2006. After the DC was performed, all 
the bone autografts removed were stored in the same freezer at -70 degrees, with 
patient identification data stored in the same room. Among all these data, we 
selected all 102 surgeries performed to lower intractable intracranial pressure 
between 2000 and 2006. For the first DC study (DC after SAH study), we excluded 
the standard indications of DC, such as TBI and malignant media infarction, 
leaving a study group of 42 patients: 29 SAH patients and 13 patients with other 
indications, including 2 each of unruptured aneurysm, arteriovenous malformation 
(AVM), fulminant demyelinating disease, virus encephalitis, and intracerebral 
haemorrhage, and one each of esthesioneuroblastoma and sinus thrombosis.  
For the other DC study (DC after TBI), we found in total 56 cases of DC having 
been performed to lower intractable ICP after TBI. We excluded 2 children under 
age of 10, and therefore our study group consisted of 54 patients (Figure 7.).  
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Figure 7. Patient selection for the DC studies. 
PATIENT SELECTION FOR THE SAH STUDY 
 
For the SAH study, patients were originally selected prospectively for a 
randomized, placebo-controlled study of the effectiveness of enoxaparin treatment 
of SAH patients. The original study showed no effect on the outcome, infarction or 
blood clotting status between the two original study groups [Siironen 2003]. The 
patients were selected among 546 aneurysmal SAH patients treated during the 
study period between February 1998 and March 2001 in our institution. The 
general inclusion criterion for the original study was radiologically verified 
aneurysmal SAH. The exclusion criteria concerned study drug administration: 1) 
hospital administration occurred later than 72 hours from SAH; 2) age over 75 
years; 3) post-operative ICH larger than 20mm; 4) any pre-existing bleeding 
disorder; 5) severe hypertension (>200/110 mmHg), renal of liver failure or pre-
existing neurological illness; 6) pregnancy or allergy to study drug; 7) post-operative 
anaemia or coagulopathy. Of the 546 SAH patients, 178 fulfilled the enrolment 
criteria and were accepted to the study. All patients or their closest relatives gave 
written consent for participation before entry into the study. 
DATA COLLECTION AND FOLLOW-UP METHODS  
 
The medical records of all the patients (620) in all four studies were examined and 
the baseline and treatment data was gathered. From medical records, all the 
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recorded information of the patient’s previous condition, the current illness, the first 
aid and paramedics’ information, condition on admission, treatments, operational 
treatments, laboratory results, and CT scan results were studied, and if there were 
data from further care, those were studied as well. At the beginning of our study, 
the patient status, date of death for those deceased and the recorded addresses for 
survivors were established from the Central Population Registry by phone inquiry.  
In the Step-Down Unit study, the survivors received 6-month, 1-year and 2-year 
questionnaires, and their answers were recorded in the database. The 5-year inquiry 
was performed by interviewing the patients over the phone (126 patients or patients’ 
caregivers). The 7 patients without a known telephone number received 
questionnaires. Of the 143 patients, 10 were lost to follow-up. The response rate 
was 93%. The first three questionnaires contained 15D questionnaires, which were 
compounded by additional questions about the type of residence, continuance of 
treatment, and management of daily living, and was meant for evaluating the 
outcome. In the 5-year inquiry, the 15D form was replaced by the EuroQol EQ-5D 
questionnaire.  
For the DC studies and the SAH study, patients were sent somewhat similar 
questionnaires as in the first study about their outcome, including EQ-5D 
questions. For these three studies, we also asked about the patient’s ability to work 
after the illness. In the DC after SAH study, each patient answered a written 
questionnaire, and in the DC after TBI study, the patients were interviewed over 
the phone. In both studies the response rate was 100%. For the SAH study, a 
written questionnaire was mailed to the survivors and the response rate was 95%. 
 
COSTS 
 
All the costs of the neurosurgical treatment period of each patient of these 4 studies 
were obtained from the Ecomed PP database (Datawell Ltd., Espoo, Finland), 
where all cost data concerning the treatment of individual patients in the hospital is 
routinely stored. The hospital stay costs included all expenses of a treatment period; 
inpatient days, medical treatments, laboratory and radiological investigations, and 
outpatient visits. Data on other costs such as treatment in any other establishment 
or any rehabilitation were not available, and thus were not included in the cost-
effectiveness calculations of the direct neurosurgical treatment. The data was 
gathered from the “Musti” program by entering the patients’ social security 
numbers and then searching for costs from the department of neurosurgery during 
the time period of the illness and treatment. 
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In the DC studies, we conducted a more precise evaluation of the total costs. The 
estimations of the total treatment costs were based on the data received from the 
patients. Patients were asked what kind of further treatment they received, where 
and how long. Medical records were also checked for further treatment data when 
available. The cost estimations were calculated according to the detailed healthcare 
cost data from the National Research and Development Centre for Welfare and 
Health publications [Hujanen 2008]. The calculations also included estimations of 
the future costs of all survivors, based on their reply, how they live (home, nursing 
home, hospital) and whether their treatment continues in some way (doctor visits, 
physiotherapy, etc.) (Figure 8.). The estimation also included the costs of the non-
survivors before they deceased, assuming they spent their last days in hospital. The 
sum of the total costs was achieved by adding the costs of treatment in our 
department, costs of further treatment for the eventual non-survivors, costs of the 
further treatment for survivors and estimation of the future treatment for the 
survivors. It was assumed that eventual non-survivors were hospitalized until the 
end of life. 
In the SAH study, we gathered only the direct neurosurgical costs and the total 
costs were approximated using the results of previous studies, in which we 
concluded the total cost to be seven times the acute cost. Because the treatment 
period occurred over 10 years ago, the figures were corrected by annual average 
inflation rates, which were obtained from the Statistics Finland website. 
 
CALCULATION OF QALYS AND COSTS 
 
The QALYs were calculated by evaluating the HRQoL index and life expectancy. 
The HRQoL index was evaluated by a EQ-5D questionnaire. The answers yielded 
a 5-digit sequence, which was converted into a weighted health state index by 
applying scores from EQ-5D “value sets,” achieved from general population 
samples. We used value sets which were derived by a choice-based method (Time 
Trade-Off, TTO). The HRQoL index was derived for each patient individually 
according to their answers. Then the life expectancy was derived also individually 
for each patient. The tables of life expectancy and death risk by age and sex for the 
Finnish population came from Statistics Finland. Life expectancies were corrected 
based on the patients’ diagnoses. The effect of each diagnosis on life expectancy 
was studied based on the literature. We had no control group to compare the results 
with. The QALY calculations were based on one group of patients in each study. 
We calculated the number of gained QALYs by subtracting the number of QALYs 
after an intervention with the number of QALYs before the intervention. The 
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HRQoL index was assumed to be 1 (best possible) before illness, but the life 
expectancy was assumed to be equal to zero (i.e. dead) without intervention, and 
therefore QALYs before the intervention were equal to zero. The non-existing life 
expectancy without intervention was supported by the extremely poor condition of 
the study patient. No one in the first three studies was assumed to survive without 
treatment. After QALYs for each patient were calculated, the QALYs were added 
up to achieve the total number of the QALYs of the survivors. Then to calculate a 
cost per one QALY, all the costs (as explained previously) were added together and 
this amount was divided by the total number of QALYs.  
 
 
 
Figure 8. Example of one patient in studies 2 and 3 to illustrate the calculation of 
the costs. 
 
Direct neurosurgical costs, retrieved from the database 47 200 €
Further care cost per day number of days costs
Secondary care unit 300 € 21 6 300 €
Primary care unit 141 € 20 2 820 €
Rehabilitation center 300 € 14 4 200 €
Nursing home 83 € 0 0 €
13 320 €
Outpatient services cost per visit number of visits
Doctor appointments 82 € 10 820 €
Physiotherapist 41 € 200 8 200 €
Speech therapist 72 € 30 2 160 €
Occupational therapist 54 € 30 1 620 €
12 800 €
Approximated future costs
Patient visits the doctor once a year, has physiotherapy once a week
and visits Rehabilitation centre once a year for two weeks.
Life expectancy 14 years
Cost per day/visit Costs per year Costs for life
Doctor appointments 82 € 82 € 1 148 €
Physiotherapist 41 € 2 050 € 28 700 €
Rehabilitation center 300 € 4 200 € 58 800 €
88 648 €
Direct neurosurgical costs 47 200 €
Further care costs 13 320 €
Outpatient costs 12 800 €
Approximated future costs 88 648 €
TOTAL 161 968 €
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STATISTICAL ANALYSIS 
 
Statistical analysis was performed with the Windows software PASW Statistics 18, 
2009. The EQ-5D HRQoL indices were calculated with the PASW syntax from the 
EuroQol Group. The normality of the data was tested (Kolmogorov-Smirnov test). 
The results were given as mean ± standard deviation (SD) or as median and 
percentiles (25th and 75th). The significance of the difference was estimated either 
with the Student t-test (Gaussian) or the unpaired Mann-Whitney U-test (non-
Gaussian) and the correlation of variables was evaluated by calculating the non-
parametric Spearman correlation coefficient (ρ); p≤0.05 was considered to be 
statistically significant.   
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RESULTS 
 
A total of 620 patients took part in the four studies (Figure 9.). The median age of 
the patients in studies 1 to 4 was 58, 48, 37 and 50 years respectively.  
 
 
Figure 9. Number of study patients and gender distribution. 
 
The distribution of the clinical condition of the patients on admission was assessed 
(Table 3.). The DC after TBI study had the most severely ill patients: 64% of the 
patients were considered to have a GCS value of less than 7. On the other hand, the 
SAH study patients had the best clinical condition on admission: 54% had WFNS 
I, which is comparable to GCS 15. 
 
 
 
 
0
50
100
150
200
250
300
350
400
STUDY 1 n=346 STUDY 2 n= 42 STUDY 3 n=54 STUDY 4 n=178
male
female
45 
 
Table 3. Clinical condition of the patients on admission to the hospital. 
GCS  
score 
Step-down 
unit study 
DC after 
SAH study 
DC after 
TBI study 
WFNS  
score 
SAH study 
 
15 16% 38% 5% I 54% 
13-14 9% 10% 13% II - III 25% 
7-12 23% 14% 18% IV 16% 
<7 52% 38% 64% V 5% 
 
 
MORTALITY AND OUTCOME 
 
The total mortalities of the studies were 59%, 53%, 41%, and 24%. Besides the total 
mortality, we were also interested when death had occurred. The cumulative 
survival is presented in Figure 10. It shows that in studies 1-3 the mortality was the 
highest soon after the first insult. Of the non-survivors, 50% died within one month 
and 70-80% within 6 months. 
 
 
Figure 10. Cumulative survival of the patients in all four studies. 
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In the Step-Down Unit study, the mortality was the highest among patients 
suffering from a malignant primary brain tumour (88%), ICH (78%) or subdural 
hematoma (60%). The outcome on the Glasgow Outcome Scale (GOS) and the 
type of residence in all four studies are presented in Tables 4-7. 
 
Table 4. Outcome of the 143 survivors in the Step-Down Unit study. 
 
  Survivors 
 
Outcome Good (GOS 1-2) 
Moderate (GOS 3) 
Poor (GOS 4) 
Lost to follow-up 
70/143 (49%) 
63/143 (44%) 
0/143 (0%) 
10/143 (7%) 
Type of residence Home 
Home assisted 
Nursing home 
Hospital 
Lost to follow-up 
70/143 (49%) 
28/143 (20%) 
32/143 (22%) 
3/143 (2%) 
10/143 (7%) 
 
 
Table 5. Outcome of the 20 surgery survivors in the DC after SAH study. 
 
  Survivors 
 
Outcome Good (GOS 1-2) 
Moderate (GOS 3) 
Poor (GOS 4) 
5/20 (25%) 
14/20 (70%) 
1/20 ( 5%) 
Type of residence Home 
Home assisted 
Nursing home 
Hospital 
10/20 (50%) 
6/20 (30%) 
3/20 (15%) 
1/20 (5%) 
 
 
Table 6. Outcome of the 32 survivors in the DC after TBI study. 
 
  Survivors 
 
Outcome Good (GOS 1-2) 
Moderate (GOS 3) 
Poor (GOS 4) 
22/32 (69%) 
8/32 (25%) 
2/32 ( 6%) 
Type of residence Home 
Home assisted 
Nursing home 
Hospital 
25/32 (78%) 
1/32 (3%) 
5/32 (16%) 
1/32 (3%) 
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Table 7. Outcome of the 135 survivors in the SAH study. 
 
  Survivors 
 
Outcome Good (GOS 1-2) 
Moderate (GOS 3) 
Poor (GOS 4) 
Lost to follow-up 
101/135 (75%) 
27/135 (20%) 
0/135 (0%) 
7/135 (5%) 
Type of residence Home 
Home assisted 
Nursing home 
Hospital 
Lost to follow-up 
119/135 (88%) 
4/135 (3%) 
5/135 (4%) 
0/135 (0%) 
7/135(5%) 
 
 
HEALTH-RELATED QUALITY OF LIFE, QALYS AND COSTS 
 
The health-related quality of life was assessed as a median EQ5D index (Table 8.). 
The DC after SAH study patients had the lowest EQ-5D index, 0.41. Particularly 
the SAH group in study 2 had poor HRQoL with the median index 0.15. The Step-
Down Unit study patients had an almost surprisingly good EQ-5D index, 0.71, 
considering the basis of the study. The index of the DC after TBI study patients 
reached the level of the standard population (0.85) and the index of the SAH study 
patients even exceeded it (Figure 11.). Figure 12 shows the EQ-5D health states of 
all 4 studies. The poor outcome of the study 2 group is also evident in the figure, 
since the majority of the patients reported having either moderate or extreme 
problems in mobility, self-care or usual activities. What is reassuring is that a 
minority of the patients reported having anxiety or depression and none reported 
pain or discomfort. The health states of the patients in studies 3 and 4 were good, 
which is evident by the good index number. 
The total costs of the treatments in studies 1 to 4 were 6.00 million €, 1.66 million 
€, 2.01 million €, and 1.75 million €. The median number of QALYs, costs per 
patient, the neurosurgical costs and the total costs for a QALY are presented in 
Table 8. 
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Figure 11. Percentages of good outcome, living at home and HRQoL being equal 
or higher compared to the reference population.  
 
Table 8. Treatment costs and costs per QALY. 
 Step-
down unit 
study 
DC after 
SAH study 
DC after TBI 
study 
SAH study 
Median EQ-5D index (25th 
and 75th percentile)  
0.71 
(0.38, 
0.85) 
0.41 
(0.02, 0.7) 
0.85 
(0.56, 1.00) 
1.00 
(0.80, 1.00) 
Total number of QALYs 
achieved 
 
2392 333 865 1036 
Mean/median QALYs per 
patients  (±SD/25th and 75th 
percentile) 
17 
±13 
16 
(1, 30) 
35 
(17, 41) 
23 
(16, 31) 
Total costs of all patients 
 
 
6 000 000€ 1 660 000€ 2 010 000€ 1 750 000€ 
Median cost of the 
treatment per patient 
(25th and 75th percentile) 
15 000€ 
(10 000-
22 000€) 
38 000 € 
(27 000, 
50 000€) 
40 000€ 
(22 000, 
48 000€) 
9 000€ 
(7 200,  
11 500€) 
Neurosurgical costs per 
QALY 
 
2 521€ 5 000€ 
 
2 400€ 1 700€ 
Estimated total costs per 
QALY 
 
29 000€ 58 000€ 17 900€ 12 000€ 
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Figure 12. EQ-5D health states in all 4 studies of all survivors included in 
follow-up. 
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ADDITIONAL FINDINGS 
 
Besides the main interest of cost-effectiveness, we discovered some interesting 
additional findings.  
1.) Recovery took longer than was expected 
In Study 1, patients answered four questionnaires between 6 months and 5 years 
after the treatment. Based on these answers, we discovered that the patients 
experienced rehabilitation for longer than generally is expected. The usual opinion 
is that after traumatic brain injury, recovery is expected to be mostly achieved 
within 1.5 years (29).  
2.) Complications of DC had no influence on the outcome 
In Study 2, we found complications after either DC or cranioplasty to be fairly 
common, infection and hydrocephaly being the most frequent. The percentage of 
complications was 60% after DC and 35% after a cranioplasty. Complications, 
however, seemed to have had no influence on the overall outcome in this study. 
The mortality for those with complication was 44%, versus those without 
complications at 65%; both groups had the same percentage (12%) of good outcome 
(GOS 1–2). 
3.) Alcohol abusers had a higher mortality and a worse outcome in TBI 
In Study 3, we examined the patients’ alcohol use before and at the time of the 
accident. We found that alcohol-related accidents were common, and of the study 
group,  50% were under the influence of alcohol at the time of injury and 30% had a 
history of habitual alcohol or substance abuse documented in their medical records. 
The habitual alcohol users had both a higher mortality (30% vs. 65%, p<0.001) and 
a worse outcome among the survivors (GOS1 17% vs. 37%, p<0.001). There were 
no explaining factors for this finding in the type of the accident, as alcohol abusers 
tend to have more common falls and assaults, whereas  others had more high-
energy trauma, such as traffic accidents. 
4.) In SAH, the previous health status had no correlation with the outcome 
In study 4, we examined several variables to find a correlation with the outcome. 
We found a statistically significant correlation between age and the outcome. But 
surprisingly no statistically significant correlation was found between the outcome 
and gender, hypertension, coronary artery disease, alcohol abuse or smoking status.  
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DISCUSSION 
 
Based on these studies of four different groups of neurosurgical patients, we found 
that the treatment was cost-effective. We also found that despite the severity of the 
illnesses, the health-related quality of life of the study groups proved to be good, 
with one exception. The majority of the patients of each study were able to live at 
home (69%, 50%, 78%, and 88%) and a large portion were able to live 
independently (48%, 25%, 69%, and 75%). 
 
ECONOMIC EVALUATION 
 
Economic evaluation of health care has many advocates, but also opponents. There 
may be opinions that health care should not be subjected to economic evaluation or 
that decisions such as “to treat or not to treat” should not be affected by money. 
That is understandable at the individual level and eventually no one should be in 
the position that necessary treatment is denied solely by monetary reasons. These 
decisions should be determined at a different level.  
When health care costs are paid from public funds, there has to be a common 
policy on what, when and how medical conditions are treated. The economic 
evaluation should be utilized to establish a bigger picture where it is a very valid 
and needed tool for resource allocation. The question is not who will be left 
without, but how the resources are divided in a way that a largest amount of health 
is achieved.    
 
EVALUATING HEALTH-RELATED QUALITY OF LIFE 
 
Although the concept of HRQoL has gained a lot of success and its use is highly 
recommendable, there are some questions in assessing the HRQoL. What is the 
influence of personality on HRQoL evaluation? How does the "bad day" affect 
assessment of HRQoL? How will several comorbidities affect estimations of a 
particular disease in research? Different methods of evaluation are influenced in a 
different way by the disturbing factors. The most sensitive method is VAS 
evaluation, in which respondents are asked to give a numerical value for their 
52 
 
HRQoL. On the other hand, more precise results are achieved with descriptive 
questionnaires, which are less influenced by other factors than HRQoL. The less 
complicated the questionnaire is, and the less freedom of choice there is, the less the 
result is affected by any other factors. This can be easily understood; if the 
questionnaire asks “can you walk or not?”, the question most likely reflects the 
actual health status rather than personality, mood, life situation or other irrelevant 
concerns. Although uncomplicated questionnaires can be free from inappropriate 
influences, they are incapable of distinguishing fine distinctions between different 
health states. 
QUALITY-ADJUSTED LIFE YEAR 
 
As well as HRQoL, the concept of QALY is widely used, but it has also received a 
lot of criticism [Hirsky 2007]. Especially in drug research, the QALY has been 
judged as too rigid and not detecting small improvements of health. It does not take 
personal differences into account in the valuing of health and it does not regard 
willingness to take risks or to pay for an illness [Stevens 2012]. QALYs have also 
been considered to discriminate elderly patients, because their life expectancy is 
lower. There are also suspicions that in chronic diseases, psychiatric disorders or 
dementia or other memory disorders, QALYs are not reliable [Bosanquet 2005]. 
However, QALYs do not, of themselves, provide a measure of cost-effectiveness. 
For example, the calculation of a ratio – the incremental (ICER) cost per QALY – 
diminishes the effect of the age in calculations. If two interventions are compared 
and ICER costs are evaluated, the effect of age does not affect the results. It is true 
that the QALY might be rigid and does not consider any personal aspects of health 
status, but should they be taken into account? Is one’s illness more important if its 
effect is greater because of personal characteristics?  
Despite the criticism against the QALY, there have not been any suggestions for 
replacing  the QALY. Finding a corresponding concept that is objective, rational, 
mathematical, universally valid, and which overcomes the deficiencies of what the 
QALY is accused of seems less than plausible. 
 
EQ-5D 
 
We selected the EQ-5D questionnaire because it is simple, clear, and quick to fill. 
We presumed that our study groups will find it easy to answer and therefore we 
expected a good response rate. There are no common recommendations or “a 
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golden standard” on which instrument to use in HRQoL studies, but in 2002, the 
Brussels Roundtable Consensus meeting recommended the SF-36 and EQ-5D as 
the preferred HRQoL instruments in the critical care setting [Angus 2002]. EQ-5D 
has had quite a few critical appraisals in the literature. In chronic pain assessment, 
EQ-5D was suspected to be influenced by the floor effect in pain assessment and 
therefore was not regarded to be sensitive enough [Dixon 2011]. Linde et al. 
compared 5 instruments, including EQ-5D, in rheumatoid arthritis and found all of 
them to be equally useful [Linde 2008]. The validity of EQ-5D has not been studied 
with acutely ill neurosurgical patients. 
Before we chose EQ-5D, we examined other possible instruments. The 15D 
questionnaire was also found suitable for our purposes. 15D is a widely used 
instrument in Finland and some institutions have prioritized its use in HRQoL 
studies. The 15D group published a study in which they found 15D to be superior 
over EQ-5D [Vainiola 2010]. However, EQ-5D is short and concise and therefore 
easy to answer and yet manages to examine the clinical condition extensively. We 
suspected 15D to be too long and contain too personal questions for our patients.  
 
COSTS ANALYSIS 
 
One of the most challenging aspects in CE studies is the evaluation of the costs. 
Even though the direct costs are recorded, they might be far from the actual costs of 
the treatment and further of the illness. The direct costs from one institution can be 
evaluated with reasonable accuracy, as these costs are well recorded. The most 
reliable estimate of the total costs may be achieved from the register of the Social 
Insurance Institution of Finland, but even that estimation may be imprecise. The 
data is based on register information, the reliability of which depends on the 
accuracy of the announcements of the health care personnel. However, this is not 
the only fact which could distort the evaluations. Patients may suffer from multiple 
illnesses and conditions and the costs may be entangled with each other.  
The complexity of the costs analysis is, however, a well-recognized and universal 
challenge. As this is difficult for all CE researchers, the most important thing in 
studies is to carefully report the methods of how and what is taken into account, 
how calculations are conducted and what the approximations are based on. 
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EFFECTIVENESS OF AN INTERVENTION 
 
In elective surgery, the assessment of the effectiveness of the intervention can be 
straightforward. The patients can be interviewed before and after the operation and 
the estimation of QALYs gained can be executed after a single surgical 
intervention. Pharmaceutical research has also utilized QALYs in assessments of 
the effect of drugs, and this may also be quite straightforward. The assessment of 
QALYs gained by intervention in acute illnesses involves many challenges. The 
evaluation of HRQoL before the treatment in acute conditions is rarely available. 
How to estimate the quality of life – could HRQoL be reliably evaluated by 
retrospective interviews? Or is it even possible to evaluate the effect of the treatment 
by using QALYs in acute serious illnesses? When an otherwise healthy person 
comes down with a serious illness, the reduction of HRQoL is inevitable and the 
assumed positive effects of the intervention may not be evident due to the sudden 
course of the illness. Another factor is the effect of the illness on the life expectancy. 
If the intervention is performed as a life-saving procedure, one could assume that 
life expectancy before treatment is equal to zero, and therefore there is no need to 
evaluate HRQoL before treatment. 
Finally, the question is how can the calculated QALYs be valued? In terms of 
medicine, are the achieved QALYs in accordance with the improvement of the 
clinical condition? How to value QALYs if there is no evidence of improvement of 
any measurable medical parameters? A weight loss study was published in NEJM 
in 2013, in which weight loss was compared between two groups, a regularly 
supported group and a control group [Nanchahal 2013]. There was no statistically 
significant difference in weight loss between the two groups, but the supported 
group reported improved HRQoL. Although there were no QALYs calculated, the 
improving HRQoL may yield QALYs. How to value QALYs achieved by this kind 
of intervention? Does the improvement of HRQoL justify the treatment even 
though the actual medical benefits of weight loss may not be achieved? 
 
COST-EFFECTIVENESS THRESHOLD 
 
The cost-effectiveness threshold is probably the most criticized component of the 
CE studies. Criticism is expressed from both sides of the table. The health care 
providers regard the limits as too low and the payers as too high, even though the 
limits are rarely expressed explicitly. The threshold limits, as well as the QALY 
concept, have faced severe criticism from the drug industry. Typically this has 
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occurred whenever a new developed drug has been declared not to be cost-effective. 
The criticism is partially justified; the declared limits of cost-effectiveness and the 
threshold are not based on any theoretical foundation. The limits are often vague 
and the decision process is not transparent. In an ideal world, the limits are well 
founded, transparent, equal, even-handed, the same to all people but still flexible. 
The theoretical bases may be impossible to establish, but since the eventual payers 
of the services are the citizens, the public opinion of willingness to pay should be 
somehow incorporated into the decision making. 
 
CONSOLIDATED REPORTING STANDARDS 
 
The health evaluation studies encounter many challenges as speculated previously. 
As the number of studies increases, the heterogeneity of the publications also 
increases. In order to be considered convincing, the study methods have to be valid 
and the reporting should be universal. Despite a growth in published studies, the 
existing reporting guidelines are not widely acknowledged or utilized. Therefore a 
panel of distinguished health economists have very recently published Consolidated 
Health Economic Evaluation Reporting Standards (CHEERS) [Husereau 2013 
(Value in Health), Husereau 2013 (BMC Medicine)]. They have published a user-
friendly checklist with the purpose of helping authors, editors, and peer reviewers to 
use the guidelines to improve reporting. The checklist includes 24 items which give 
explicit instructions for every section, topics ranging from the title of the report to 
the source of funding and conflicts of interest. These kinds of universal guidelines 
are very welcome and it is in every researcher’s interest to utilize these guidelines. 
The more consistent the methods and reporting standards are in publications, the 
more weight will publications and the whole field of health economics gain. 
Uniform methodology makes it possible to compare the results of studies, 
treatments and different fields of medicine, etc. Even though a major part of this 
research project has been conducted before the guidelines were published, all of the 
four studies in the research project fulfill the requirements of the guidelines for the 
most part.    
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STEP-DOWN UNIT STUDY 
  
The purpose of the Step-Down Unit study was to evaluate whether the treatment 
policy in our department was clinically justified and cost-effective or whether it was 
a worthless extension of humane suffering at high costs. 
The main limitation of the Step-Down Unit study was the heterogeneity of the 
study group and lack of unambiguous inclusion criteria. We did not evaluate the 
outcome of a specific diagnosis, but had a study group of step-down unit patients in 
a poor condition with various neurosurgical diagnoses. The decision to withdraw 
patients from a neurosurgical intensive care unit and move them to the step-down 
unit was made by a senior neurosurgeon. There were no objective measures, such 
as a laboratory result, but the decision was based on an evaluation of whether the 
patients would benefit from ICU treatment or not. The baseline assumption was 
that these patients would have died without treatment and, furthermore, if these 
patients would have been disconnected from life-sustaining devices at the time of 
discharge from the ICU, they would have died. Therefore, we concluded that the 
combination of treatment including operational and intensive care treatment as well 
as extra time spent in a step-down unit was a life-saving intervention for survivors. 
This fundamental assumption was utilized in QALY calculations, and the high 
mortality of the study group indicates that our assumption was likely to be correct.  
 Another obvious shortcoming was the cost analysis in which only the direct 
neurosurgical costs were calculated, though most of the patients were transferred to 
other hospitals for further care, where cost data were not available. The total costs 
were assessed by using estimates presented in the literature and by performing 
estimations based on questionnaire data of the patient's type of residence (assisted 
at home, a nursing home, or a hospital) and continuance of the treatment (e.g. 
physical and speech therapy) and on detailed healthcare cost data from publications 
of the National Research and Development Centre for Welfare and Health. We 
calculated the approximations of the costs during study time. Furthermore, we 
made estimations for the future costs based on these same data. Finally, we 
included the approximated costs of the eventual non-survivors. 
In the QALY calculations, we aimed to be as precise as possible. We calculated the 
reduction of HRQoL by age using the values of the standard population.The effect 
of the specific diagnosis on life expectancy was also taken into account. We 
performed a literature search for the most valid approximations and reduced the life 
expectancy accordingly.  
Acknowledging these limitations, this study succeeded in showing that despite a 
poor prognosis, the treatment was justified and many patients experienced better 
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recovery than anticipated and, the treatment in the step-down unit has been 
developed further based on these findings. 
 
DC AFTER SAH STUDY 
 
As discussed previously, the status of DC has been controversial in the literature as 
long as it has been utilized. Before our study, there were no cost-effectiveness 
evaluations of DC of any underlying etiology. Our aim was to perform the first 
cost-effectiveness study on DC patients. This study focused on patients whose DC 
was performed in non-traumatic rise of ICP. DC has been relatively rarely used on 
SAH patients and literature on the topic is very limited, but the outcome is 
presumed to be poor. 
The most obvious limitation in the DC after SAH study is the lack of any non-
operative treatment group with which to compare the results. However, as 
discussed previously, conservative treatment would be hard to justify, knowing that 
DC often normalizes increased ICP in the acute phase, though the long-term effects 
are controversial. 
The main challenge in this study was analyzing and interpreting the results because 
the underlying etiology leading to the DC was so heterogeneous, causing also large 
variation in the results. The study group had to be divided into two groups (SAH 
and other neurological emergencies), which further reduced the number of patients 
in the groups. The results of the SAH group were similar to previous results in the 
literature, but the other group lacked comparable references because of the rarity of 
the illnesses. Therefore, as the indications for DC in various situations were not 
established, the results cannot necessarily be generalized to cover different clinical 
situations.   
There were no common and specific indications or contraindications in SAH or 
other neurological emergencies for performing DC. Our assumption was that DC 
was the last possible intervention when all other means had failed. The clinical 
condition of the patients before DC was poor; all were comatose, in respirators, 
ICP extremely high (over 35 mmHg), and many had either fixed, dilated pupils or 
herniation in the CT scan. There were no contraindications for DC other than 
death. From this point of view, the results could be considered quite acceptable. In 
the QALY calculations, we did not calculate QALYs before the illness because we 
assumed that life expectancy without treatment would be equal to zero, resulting in 
QALY before the illness being zero. Considering the poor condition of the patients 
before DC, this assumption seems to be justified. 
58 
 
Despite the limitations, the study implicated that patients with intractable ICP due 
to various underlying etiologies (other than SAH) may benefit from DC, as they 
seemed to recover fairly well. The HRQoL index for SAH patients was poor, only 
0.15, and only one of the 11 SAH survivors had returned to work. On the other 
hand, 8 of the 11 were able to live at home. Then again, considering the fact that 
without the treatment they would most likely die, their outcome can be considered 
at least reasonable. The cost of neurosurgical treatment for one QALY was 11,000€ 
for SAH and 2,000€ for other emergencies. DC after other indications seems to be 
justified and cost-effective, but the use of DC for SAH patients should be 
predisposed for further evaluation. DC should be performed only after careful 
consideration, since there was no convincing evidence of its benefits. 
  
DC AFTER TBI STUDY 
 
Although there are studies on DC performed after TBI, no consensus exists of its 
benefits, and the economic aspects of the procedure have not been studied. We 
aimed to demonstrate that DC is a cost-effective procedure and its use is well 
grounded for vital indications. 
As previously in the DC after SAH study, also in this study the most obvious 
limitation was the lack of any non-operative treatment group with which to 
compare the results. There are no randomized control trials on hemicraniectomy, 
and such studies will probably not appear until a major step forward is taken in 
conservative treatment. One subject of discussion was the indications and 
contraindications for DC. So called “prophylactic” DC was not performed in our 
study group. Each patient who underwent DC was considered to be fatally ill and 
therefore we presumed that DC was performed for vital indications. Before DC, 
patients had either ICP over 35, dilated pupils or brainstem herniation seen in a CT 
scan. The contraindication raised questions as well because we were not able to 
give exact boundaries or values for exclusion since there were none. Anyone who 
was expected to survive through the surgery received DC, except patients with a 
brainstem hematoma. 
In the cost analysis, our goal was to create a more accurate approximation of total 
costs. We gathered information from patients and medical records about treatment 
after the acute treatment period, evaluated all the treatment costs of deceased, and 
we also estimated the future costs based on the information of the continuance of 
treatment.  
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This study indicated that DC is a beneficial procedure for TBI patients and the 
recovery of the patients was surprisingly good. The treatment was estimated to be 
both clinically justified and cost-effective, and therefore the use of DC could be 
recommended for treating similar patients. 
 
SAH STUDY 
 
The purpose was to perform a long-term outcome evaluation of SAH patients. 
Many studies focus on the outcome at 6-12 months after SAH, but we performed an 
evaluation of the outcome approximately 10 years after treatment. The cost-
effectiveness of the treatments was also evaluated. 
The most obvious limitation of the SAH study is the cost evaluation. The direct 
neurosurgical costs were collected from the actual hospital cost database and may 
therefore be considered reliable. However, most of the patients were transferred to 
other hospitals for further care and rehabilitation, and the exact cost data from these 
facilities were not available. The total costs were evaluated by estimations found in 
the  literature. The recovery of the study patients was amazingly good and therefore 
the total costs are not expected to exceed these evaluations. Another issue for 
speculation was whether the good outcome was due to the strict inclusion criteria. 
The study group was originally recruited to study the effect of anticoagulant drugs 
on SAH patients, and therefore the exclusion criteria mainly concerned the drug 
administration. However, the case fatality of our patients was relatively high, 
suggesting that it represents well the hospital-based SAH population.  
Acknowledging the shortcomings of the analysis, this study still managed to 
confirm the good recovery of the patients. After a ten-year follow-up, 75% of the 
survivors had a good outcome as evaluated on the GOS scale. Another measure of 
well-being is the ability to return to work. Of our survived patients, 63% returned to 
work after SAH, and at 10 years into the follow-up, 36% were still working and 
27% had retired because of age. Only 24% reported that they do not work because 
of SAH. The EQ-5D index and the VAS value were similar or even better than the 
reference population’s values. Reasons for this can be only speculated; it could be 
that after a serious illness, patients have a healthier life style, better control of 
chronic illnesses, or the evaluation and appreciation of one’s health status may 
change after being seriously ill. 
We found the treatment to be cost-effective, and this study may be encouraging for 
SAH patients and their next-of-kin, giving hope that the original survivors may 
have a good recovery.   
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CONCLUSIONS 
 
The rising medical costs and the growing at-risk population will lead to increasing 
competition for health care resources. While competing for resources, different 
branches of medicine are forced to demonstrate the benefits of their treatments. The 
treatment of the most severely ill neurosurgical patients is highly resource-
demanding and is therefore a potential target of doubts regarding whether the 
treatment of these patients is cost-effective or even clinically justified.  
We have studied a total of 620 severely ill neurosurgical patients treated in the 
Helsinki Department of Neurosurgery between 1998 and 2006. We found the 
treatment of the severely ill neurosurgical patients to be cost-effective, which 
resulted in health-related quality of life that varied from acceptable to good when 
compared to the reference population. We found no evidence of unnecessary 
prolongation of human suffering when death was inevitable. The worst state of 
health-related quality of life did not occur among the survivors. However, the status 
of DC in the treatment of SAH patients should be subjected for further evaluation.  
In summary, the current healthcare resources are utilized cost-effectively to achieve 
life that is meaningful. Allocation of healthcare resources to severely ill 
neurosurgical patients seems to be justified.    
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